MUCOSALLY-APPLIED AGENT FOR PREVENTION, AMELIORATION OR TREATMENT OF RETINAL DISEASE
申请人:ROHTO PHARMACEUTICAL CO., LTD.
公开号:US20140243419A1
公开(公告)日:2014-08-28
Application of a pharmaceutical preparation comprising geranylgeranylacetone to the mucosa of, for example, the eye, nose, oral cavity or pharynx can efficiently prevent, ameliorate or treat retinal diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy.